Zelira faces ASX removal after failing to pay listing fee by Adam Sheldon August 24, 2026August 24, 2026 Zelira Therapeutics is facing removal from the Australian Securities Exchange (ASX) after failing to pay its […]
Financial news in brief: Avecho; InhaleRx; Neurotech; Peak; Zelira; Argent by Adam Sheldon February 2, 2026June 8, 2026
News in brief: Epsilon receives EU, UK GMP certificates; AGH raises $2.6m via placement; Zelira secures loan notes; Bioxyne’s $5m German order by Steve Jones September 17, 2025February 21, 2026
News in brief: Shahin becomes Vitura’s largest shareholder; Avecho progresses CBD insomnia trial; Epsilon reports improved cashflow; Zelira locks in R&D loan to advance trial by Adam Sheldon July 31, 2025July 31, 2025
Company news: Leafio; SOMAÍ Pharmaceuticals; Helius Therapeutics; Zelira Therapeutics by Martin Lane January 28, 2025January 29, 2025
Company news: Avecho; Bioxyne; Elixinol Wellness; IDT Australia; Melodiol Global Health; Zelira by Steve Jones July 31, 2024November 25, 2024
Financial results: Bioxyne; Melodiol Global Health; Emyria; Zelira; Elixinol; Wellnex Life; Argent BioPharma by Steve Jones May 1, 2024May 1, 2024
Company news: Bioxyne/BLS; Rua Bioscience; Botanix; Melodiol Global Health; Zelira; Argent BioPharma by Martin Lane and Steve Jones April 16, 2024July 16, 2024
Company news: Zelira; ECS Botanics; LGP; Ecofibre; Neurotech; Elixinol; Emyria by Steve Jones and Martin Lane February 28, 2024July 16, 2024
